Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK U.S. Clinical Trial Registry Will Publicize Studies For Marketed Products

This article was originally published in The Pink Sheet Daily

Executive Summary

The registry appears to build upon an initiative launched by Glaxo Wellcome in 1998; that registry was only available to health care providers. The announcement closely follows the New York AG's lawsuit on Paxil study data, but GSK says the program has been under consideration for several months.

You may also be interested in...



GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005

The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.

GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005

The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.

Merck Support For ClinicalTrials.Gov Expansion Does Not Mean Company Will Add Listings

Merck says it prefers to continue to fly below the radar screen with respect to ClinicalTrials.gov unless the law is changed. Merck's response to AMA's clinical trials registry proposal receives national media attention, but the company is an unlikely champion for government-sponsored public trial databases.

Related Content

Topics

UsernamePublicRestriction

Register

PS059720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel